Home
Categories
EXPLORE
True Crime
Comedy
Society & Culture
Business
Sports
Technology
History
About Us
Contact Us
Copyright
© 2024 PodJoint
Podjoint Logo
US
00:00 / 00:00
Sign in

or

Don't have an account?
Sign up
Forgot password
https://is1-ssl.mzstatic.com/image/thumb/Podcasts211/v4/2c/73/33/2c7333bd-3a5c-031c-0581-0d66d2c1ed56/mza_7780240266464937600.jpg/600x600bb.jpg
IDEA Collider: Innovation & Asymmetric Learning in Pharma
IDEA Pharma, SAI MedPartners
60 episodes
1 month ago
IDEA Collider explores how asymmetric learning drives bold innovation in the pharmaceutical and life sciences industries. Hosted by Mike Rea, CEO of IDEA Pharma & Head of Strategy and Thought Leadership at SAI MedPartners, the podcast features conversations with top thinkers, scientists, and strategists who challenge the status quo to spark real progress in drug development, biotech, and healthcare. Each episode dives into how organizations can make smarter decisions earlier, reimagine R&D, and unlock competitive advantage through differentiated thinking. Questions We Explore * What is asymmetric learning, and how does it fuel pharma innovation? * Why do some organizations outpace others—and what can we learn from them? * How can we overcome barriers to meaningful progress in healthcare? * What’s broken in traditional innovation models—and how do we fix it? 🎧 Listen and subscribe on all major platforms.
Show more...
Life Sciences
Business,
Management,
Marketing,
Science
RSS
All content for IDEA Collider: Innovation & Asymmetric Learning in Pharma is the property of IDEA Pharma, SAI MedPartners and is served directly from their servers with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
IDEA Collider explores how asymmetric learning drives bold innovation in the pharmaceutical and life sciences industries. Hosted by Mike Rea, CEO of IDEA Pharma & Head of Strategy and Thought Leadership at SAI MedPartners, the podcast features conversations with top thinkers, scientists, and strategists who challenge the status quo to spark real progress in drug development, biotech, and healthcare. Each episode dives into how organizations can make smarter decisions earlier, reimagine R&D, and unlock competitive advantage through differentiated thinking. Questions We Explore * What is asymmetric learning, and how does it fuel pharma innovation? * Why do some organizations outpace others—and what can we learn from them? * How can we overcome barriers to meaningful progress in healthcare? * What’s broken in traditional innovation models—and how do we fix it? 🎧 Listen and subscribe on all major platforms.
Show more...
Life Sciences
Business,
Management,
Marketing,
Science
https://image.simplecastcdn.com/images/bc1d3cbd-f08d-4204-9d64-cacf1bd83767/e825233d-63fe-4e28-baf7-70a7ac6c737a/3000x3000/uk-books-on-table-3000x2000.jpg?aid=rss_feed
IDEA Collider | Pharma Book Club | Kat Arney
IDEA Collider: Innovation & Asymmetric Learning in Pharma
47 minutes 42 seconds
4 years ago
IDEA Collider | Pharma Book Club | Kat Arney
An interview with Dr Kat Arney, author of Rebel Cell (Note: some sensitive language content) Many of us think of cancer as a contemporary killer, a disease of our own making caused by our modern lifestyles. But, as Kat Arney explains in her new book REBEL CELL: Cancer Evolution and the Science of Life, that perception just isn’t true.
IDEA Collider: Innovation & Asymmetric Learning in Pharma
IDEA Collider explores how asymmetric learning drives bold innovation in the pharmaceutical and life sciences industries. Hosted by Mike Rea, CEO of IDEA Pharma & Head of Strategy and Thought Leadership at SAI MedPartners, the podcast features conversations with top thinkers, scientists, and strategists who challenge the status quo to spark real progress in drug development, biotech, and healthcare. Each episode dives into how organizations can make smarter decisions earlier, reimagine R&D, and unlock competitive advantage through differentiated thinking. Questions We Explore * What is asymmetric learning, and how does it fuel pharma innovation? * Why do some organizations outpace others—and what can we learn from them? * How can we overcome barriers to meaningful progress in healthcare? * What’s broken in traditional innovation models—and how do we fix it? 🎧 Listen and subscribe on all major platforms.